CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

K Phos Neutral

Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate· ingredient sodium phosphate, monobasic· POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.29006
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other sodium phosphate, monobasic products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
CVS Pharmacy$0.00637−$0.28370

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.